Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations

Next Previous
X
Search
Trial Profile

A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Litifilimab (Primary)
  • Indications Cutaneous lupus erythematosus; Discoid lupus erythematosus; Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Acronyms LILAC
  • Sponsors Biogen

    • Most Recent Events

    • 15 Nov 2023 Results assessing effects of litifilimab on IFN gene signature scores from whole blood samples, serum IFNalpha concentrations, and other serum cytokine concentrations in participants from this trial presented at the ACR Convergence 2023
    • 03 Jun 2023 Results assessing effect of litifilimab treatment on IFN gene signature (IFNGS) scores and IFN alpha levels in patients from this study, presented at the 24th Annual Congress of the European League Against Rheumatism.
    • 14 Nov 2022 Results of post hoc prespecified exploratory subgroup analyses assessing efficacy outcomes of BIIB059 in participants with cutaneous lupus erythematosus, presented at the ACR Convergence 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top